Tortugas Neuroscience Launches with $106M, Targets Schizophrenia & Tinnitus with Drugs from China's Hansoh

A new biotech startup is betting that the next wave of treatments for complex brain disorders will come from Asia. Tortugas Neuroscience launched with $106 million in funding and a pipeline built on drugs licensed from major Chinese and Japanese pharmaceutical firms, signaling a strategic shift in sourcing neurological therapies beyond the traditional Western biotech hubs.

The company's initial focus is on developing two drugs for schizophrenia and tinnitus, licensed from Chinese drugmaker Jiangsu Hansoh Pharmaceutical Group. In parallel, Tortugas will test two other medicines for focal epilepsy and encephalopathies that originated from Japanese pharmaceutical giant Eisai Co. Ltd. The substantial Series A financing, led by Cure Ventures, The Column Group, and AN Ventures, is earmarked to advance these candidates into mid-stage clinical trials in the United States.

This launch underscores a growing trend of Western biotechs leveraging Asian-developed intellectual property to accelerate drug development for challenging neurological and psychiatric conditions. The move places Tortugas at the intersection of global capital and cross-border pharmaceutical licensing, with the potential to reshape competitive dynamics in the neuroscience sector if its clinical programs show promise. The success of this model could pressure other startups to look eastward for novel compounds, increasing scrutiny on the quality and translatability of externally sourced drug candidates.